Cartesian Therapeutics In...

NASDAQ: RNAC · Real-Time Price · USD
12.33
0.33 (2.75%)
At close: May 01, 2025, 3:59 PM
12.27
-0.49%
After-hours: May 01, 2025, 04:20 PM EDT
2.75%
Bid 11.5
Market Cap 319.43M
Revenue (ttm) 38.91M
Net Income (ttm) -77.42M
EPS (ttm) -4.49
PE Ratio (ttm) -2.75
Forward PE -3.4
Analyst Buy
Ask 12.91
Volume 63,126
Avg. Volume (20D) 94,698
Open 12.02
Previous Close 12.00
Day's Range 11.56 - 12.43
52-Week Range 8.85 - 41.87
Beta 0.50

About RNAC

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2016
Employees 66
Stock Exchange NASDAQ
Ticker Symbol RNAC
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for RNAC stock is "Buy." The 12-month stock price forecast is $41, which is an increase of 232.52% from the latest price.

Stock Forecasts

Next Earnings Release

Cartesian Therapeutics Inc. is scheduled to release its earnings on May 16, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-35.02%
Cartesian Therapeutics shares are trading lower. T... Unlock content with Pro Subscription